Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection

GeneFirst has achieved another milestone this week with a clinical validation paper having been published under the VALidation of HPV GENotyping Tests (VALGENT) framework.

The Papilloplex high-risk human papillomavirus (hrHPV) test is a single tube real-time HPV test which provides multiplex detection and separate identification of 14 hrHPV types. The assay showed excellent agreement compared with GP5+/6+EIA Immunoassay using cervical specimens stored in SurePath medium, fulling the international clinical accuracy criteria for use in cervical cancer screening.

Click here to read to the full publication.